Neurogene Statistics
Total Valuation
Neurogene has a market cap or net worth of $216.78 million. The enterprise value is -$83.20 million.
Important Dates
The last earnings date was Monday, March 24, 2025, after market close.
Earnings Date | Mar 24, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Neurogene has 14.93 million shares outstanding. The number of shares has increased by 277.22% in one year.
Current Share Class | 14.93M |
Shares Outstanding | 14.93M |
Shares Change (YoY) | +277.22% |
Shares Change (QoQ) | +14.84% |
Owned by Insiders (%) | 10.92% |
Owned by Institutions (%) | 58.12% |
Float | 5.55M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 275.76 |
Forward PS | n/a |
PB Ratio | 0.69 |
P/TBV Ratio | 0.70 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 20.84, with a Debt / Equity ratio of 0.04.
Current Ratio | 20.84 |
Quick Ratio | 20.65 |
Debt / Equity | 0.04 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -6,883.75 |
Financial Efficiency
Return on equity (ROE) is -30.28% and return on invested capital (ROIC) is -19.71%.
Return on Equity (ROE) | -30.28% |
Return on Assets (ROA) | -18.49% |
Return on Invested Capital (ROIC) | -19.71% |
Return on Capital Employed (ROCE) | -25.77% |
Revenue Per Employee | $10,165 |
Profits Per Employee | -$825,758 |
Employee Count | 91 |
Asset Turnover | 0.00 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -70.52% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -70.52% |
50-Day Moving Average | 16.86 |
200-Day Moving Average | 31.76 |
Relative Strength Index (RSI) | 39.85 |
Average Volume (20 Days) | 219,737 |
Short Selling Information
The latest short interest is 2.18 million, so 14.60% of the outstanding shares have been sold short.
Short Interest | 2.18M |
Short Previous Month | 1.96M |
Short % of Shares Out | 14.60% |
Short % of Float | 39.31% |
Short Ratio (days to cover) | 12.51 |
Income Statement
In the last 12 months, Neurogene had revenue of $925,000 and -$75.14 million in losses. Loss per share was -$4.28.
Revenue | 925,000 |
Gross Profit | -3.58M |
Operating Income | -82.61M |
Pretax Income | -55.44M |
Net Income | -75.14M |
EBITDA | -79.36M |
EBIT | -82.61M |
Loss Per Share | -$4.28 |
Full Income Statement Balance Sheet
The company has $312.41 million in cash and $12.43 million in debt, giving a net cash position of $299.98 million or $20.09 per share.
Cash & Cash Equivalents | 312.41M |
Total Debt | 12.43M |
Net Cash | 299.98M |
Net Cash Per Share | $20.09 |
Equity (Book Value) | 310.38M |
Book Value Per Share | 20.89 |
Working Capital | 300.77M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$70.60 million and capital expenditures -$808,000, giving a free cash flow of -$71.41 million.
Operating Cash Flow | -70.60M |
Capital Expenditures | -808,000 |
Free Cash Flow | -71.41M |
FCF Per Share | -$4.78 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | -8,930.27% |
Pretax Margin | -8,123.68% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Neurogene does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -277.22% |
Shareholder Yield | n/a |
Earnings Yield | -34.66% |
FCF Yield | -32.94% |
Analyst Forecast
The average price target for Neurogene is $59.80, which is 311.85% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $59.80 |
Price Target Difference | 311.85% |
Analyst Consensus | Strong Buy |
Analyst Count | 5 |
Revenue Growth Forecast (5Y) | 133.70% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Neurogene has an Altman Z-Score of 10.46 and a Piotroski F-Score of 2.
Altman Z-Score | 10.46 |
Piotroski F-Score | 2 |